Literature DB >> 15341740

SKAR is a specific target of S6 kinase 1 in cell growth control.

Celeste J Richardson1, Mark Bröenstrup, Diane C Fingar, Kristina Jülich, Bryan A Ballif, Steven Gygi, John Blenis.   

Abstract

BACKGROUND: The mammalian target of rapamycin (mTOR) and phosphatidylinositol 3-kinase (PI3K) signaling pathways promote cell growth and cell cycle progression in response to nutritional, energy, and mitogenic cues. In mammalian cells, the ribosomal protein S6 kinases, S6K1 and S6K2, lie downstream of mTOR and PI3K, suggesting that translational control through the phosphorylation of S6 regulates cell growth. Interestingly, genetic experiments predict that a substrate that is specific to S6K1 but not S6K2 regulates cell growth.
RESULTS: Here we identify SKAR as a novel and specific binding partner and substrate of S6K1 but not S6K2. We find that serines 383 and 385 of human SKAR are insulin-stimulated and rapamycin-sensitive S6K1 phosphorylation sites. Quantitative mass spectrometry reveals that serine 383/385 phosphorylation is sensitive to RNA interference (RNAi)-mediated S6K1 reduction, but not S6K2 reduction. Furthermore, RNAi-mediated reduction of SKAR decreases cell size. SKAR is nuclear protein with homology to the Aly/REF family of RNA binding proteins, which has been proposed to couple transcription with pre-mRNA splicing and mRNA export.
CONCLUSIONS: We have identified a novel and specific target of S6K1, SKAR, which regulates cell growth. The homology of SKAR to the Aly/REF family links S6K1 with mRNA biogenesis in the control of cell growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341740     DOI: 10.1016/j.cub.2004.08.061

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  73 in total

1.  p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake.

Authors:  Yossi Dagon; Elizabeth Hur; Bin Zheng; Kerry Wellenstein; Lewis C Cantley; Barbara B Kahn
Journal:  Cell Metab       Date:  2012-06-21       Impact factor: 27.287

Review 2.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

Review 3.  The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes.

Authors:  Jianling Xie; Terence P Herbert
Journal:  Cell Mol Life Sci       Date:  2011-11-09       Impact factor: 9.261

Review 4.  Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak; Tomasz Grzela; Maciej Lazarczyk
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

5.  Identification of S6K2 as a centrosome-located kinase.

Authors:  Rossella Rossi; John M Pester; Mitch McDowell; Samuela Soza; Alessandra Montecucco; Kay K Lee-Fruman
Journal:  FEBS Lett       Date:  2007-07-30       Impact factor: 4.124

6.  Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity.

Authors:  Marcia D Antion; Maayan Merhav; Charles A Hoeffer; Gerald Reis; Sara C Kozma; George Thomas; Erin M Schuman; Kobi Rosenblum; Eric Klann
Journal:  Learn Mem       Date:  2008-01-03       Impact factor: 2.460

7.  Perspective: The Potential Role of Essential Amino Acids and the Mechanistic Target of Rapamycin Complex 1 (mTORC1) Pathway in the Pathogenesis of Child Stunting.

Authors:  Richard D Semba; Indi Trehan; Marta Gonzalez-Freire; Klaus Kraemer; Ruin Moaddel; M Isabel Ordiz; Luigi Ferrucci; Mark J Manary
Journal:  Adv Nutr       Date:  2016-09-15       Impact factor: 8.701

8.  Rapamycin inhibits liver growth during refeeding in rats via control of ribosomal protein translation but not cap-dependent translation initiation.

Authors:  Padmanabhan Anand; Philip A Gruppuso
Journal:  J Nutr       Date:  2006-01       Impact factor: 4.798

9.  Pdk1 activity controls proliferation, survival, and growth of developing pancreatic cells.

Authors:  Joby J Westmoreland; Qian Wang; Mohamed Bouzaffour; Suzanne J Baker; Beatriz Sosa-Pineda
Journal:  Dev Biol       Date:  2009-07-25       Impact factor: 3.582

Review 10.  Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.

Authors:  Ken Inoki; Kun-Liang Guan
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.